AbbVie Inc.

12/07/2019 | Press release | Distributed by Public on 12/07/2019 07:58

IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic[...]